Groningen, The Netherlands – 6 November 2025 – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today initiated a new formulation development program focused on a specific small molecule drug substance, reinforcing its long-standing commitment to supporting its customers across a range of molecules.
The new collaborations leverage InnoCore’s proprietary SynBiosys® biodegradable polymer platform, which enables controlled, sustained release of active pharmaceutical ingredients across a wide range of Active Pharmaceutical Ingredient (API) classes. The latest projects focus on developing extended-release injectable formulations designed to improve pharmacokinetic profiles, reduce dosing frequency, and enhance patient convenience for chronic disease therapies.
InnoCore’s small molecule expertise is built on more than 20 years of formulation and polymer development experience, with proven success in delivering scalable LAI solutions that maintain drug stability, optimise therapeutic performance and create differentiating results for its clients. The Company’s state-of-the-art facilities in Groningen provide end-to-end development capabilities, including polymer synthesis, formulation development, full analytical characterization and non-clinical supply manufacturing.
While reaffirming its ongoing partnerships in small molecule formulation development, InnoCore’s management emphasized that the company’s strategic growth trajectory remains firmly centred on the biologics and peptides reformulation segment, a rapidly expanding area of opportunity where the SynBiosys® platform provides clear competitive differentiation.
Bart Jan Korteling, COO at InnoCore Pharmaceuticals, said: “Our work with small molecule programmes has been a cornerstone of InnoCore’s success for more than 20 years. These ongoing collaborations reflect our deep commitment to delivering high-quality, science-driven solutions for all API classes. At the same time, our future focus is clear: to expand our leadership in long-acting injectable peptide and biologic formulations, where our SynBiosys® technology offers unparalleled advantages in stability, scalability, and future patient outcomes.”
As the company expands its work in peptides and biologics while maintaining its strong base in small molecule development, InnoCore continues to drive innovation in next-generation, sustained-release injectable medicines that enhance treatment efficacy, patient experience, and long-term therapeutic value.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com.